当前位置：
X-MOL 学术
›
Aliment. Pharm. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Editorial: infliximab or adalimumab as first- or second-line anti-TNF—conflicting evidence
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-08-23 , DOI: 10.1111/apt.16555 John P Haydek 1 , Frank I Scott 1
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-08-23 , DOI: 10.1111/apt.16555 John P Haydek 1 , Frank I Scott 1
Affiliation
This article is linked to Visuri et al papers. To view these articles, visit https://doi.org/10.1111/apt.16525 and https://doi.org/10.1111/apt.16569
中文翻译：
社论：英夫利昔单抗或阿达木单抗作为一线或二线抗肿瘤坏死因子——相互矛盾的证据
本文链接到 Visuri 等人的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16525 和 https://doi.org/10.1111/apt.16569
更新日期：2021-08-24
中文翻译：
社论：英夫利昔单抗或阿达木单抗作为一线或二线抗肿瘤坏死因子——相互矛盾的证据
本文链接到 Visuri 等人的论文。要查看这些文章，请访问 https://doi.org/10.1111/apt.16525 和 https://doi.org/10.1111/apt.16569
京公网安备 11010802027423号